PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
Background Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph node-positive (N +) breast cancer (BC) patients according to NCCN guidelines, it is undeniable that many patients achieved pathological complete respons...
Saved in:
| Published in | World journal of surgical oncology Vol. 21; no. 1; pp. 1 - 9 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central Ltd
18.09.2023
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph node-positive (N +) breast cancer (BC) patients according to NCCN guidelines, it is undeniable that many patients achieved pathological complete response (pCR) after trastuzumab (H)-based regimens without adding pertuzumab to treatment. Patients who specifically benefit from pertuzumab must be identified. The aim of this retrospective study was to evaluate progesterone receptor (PR) status as a predictor of response to the addition of pertuzumab in HER2 + /N + breast cancer. Methods One hundred forty-two patients who were diagnosed as HER2 + /N + BC without distant metastasis and followed by neoadjuvant HP-based or H-based therapy were retrospectively included. The endpoints were pCR and disease-free survival (DFS) times. Results In total, the pCR occurred in 25 of 87 patients (28.74%) in group H compared with 32 of 55 (58.18%) in group HP. The results revealed that hormone receptor (HR) status was significantly different on pCR in group HP. The odds of pCR for patients who have HR-positive tumors were 0.160 times (P = 0.011) that for patients with HR-negative tumors by multivariable analysis. Moreover, a similar probability of PR-positive (PR +) patients, whatever estrogen receptor (ER) status was, achieving pCR in group HP was observed. The ROC curves showed different anti-HER2 regimens provide worst predictive value in the PR + cohort (N = AUC = 0.521, 95% CI: 0.348-0.694, P = 0.813) compared with the overall cohort (AUC = 0.644, 95% CI: 0.550-0.738, P = 0.004) and ER + cohort (AUC: 0.559, 95% CI: 0.405-0.713, P = 0.451). And PR status (AUC = 0.760, 95% CI: 0.626-0.894, P = 0.001) had a greater predictive value than ER status (AUC = 0.658, 95% CI: 0.508-0.807, P = 0.048) in group HP. DFS analyses were done on 141 patients. Although ER and PR status did not show significant difference in group HP (P = 0.789 and 0.088, respectively), HP-based therapy contributed to better DFS in the ER - and PR - cohorts (P = 0.035 and 0.015, respectively). Conclusions Compared with ER status, PR status might be a more valuable factor predicting the efficacy of adding pertuzumab into neoadjuvant therapy for HER2 + /N + BC. PR + patients benefit little from the addition of pertuzumab. Keywords: HER2-positive breast cancer, Progesterone receptor, Neoadjuvant therapy, Pathological complete response |
|---|---|
| AbstractList | Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph node-positive (N +) breast cancer (BC) patients according to NCCN guidelines, it is undeniable that many patients achieved pathological complete response (pCR) after trastuzumab (H)-based regimens without adding pertuzumab to treatment. Patients who specifically benefit from pertuzumab must be identified. The aim of this retrospective study was to evaluate progesterone receptor (PR) status as a predictor of response to the addition of pertuzumab in HER2 + /N + breast cancer.BACKGROUNDAlthough neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph node-positive (N +) breast cancer (BC) patients according to NCCN guidelines, it is undeniable that many patients achieved pathological complete response (pCR) after trastuzumab (H)-based regimens without adding pertuzumab to treatment. Patients who specifically benefit from pertuzumab must be identified. The aim of this retrospective study was to evaluate progesterone receptor (PR) status as a predictor of response to the addition of pertuzumab in HER2 + /N + breast cancer.One hundred forty-two patients who were diagnosed as HER2 + /N + BC without distant metastasis and followed by neoadjuvant HP-based or H-based therapy were retrospectively included. The endpoints were pCR and disease-free survival (DFS) times.METHODSOne hundred forty-two patients who were diagnosed as HER2 + /N + BC without distant metastasis and followed by neoadjuvant HP-based or H-based therapy were retrospectively included. The endpoints were pCR and disease-free survival (DFS) times.In total, the pCR occurred in 25 of 87 patients (28.74%) in group H compared with 32 of 55 (58.18%) in group HP. The results revealed that hormone receptor (HR) status was significantly different on pCR in group HP. The odds of pCR for patients who have HR-positive tumors were 0.160 times (P = 0.011) that for patients with HR-negative tumors by multivariable analysis. Moreover, a similar probability of PR-positive (PR +) patients, whatever estrogen receptor (ER) status was, achieving pCR in group HP was observed. The ROC curves showed different anti-HER2 regimens provide worst predictive value in the PR + cohort (N = AUC = 0.521, 95% CI: 0.348-0.694, P = 0.813) compared with the overall cohort (AUC = 0.644, 95% CI: 0.550-0.738, P = 0.004) and ER + cohort (AUC: 0.559, 95% CI: 0.405-0.713, P = 0.451). And PR status (AUC = 0.760, 95% CI: 0.626-0.894, P = 0.001) had a greater predictive value than ER status (AUC = 0.658, 95% CI: 0.508-0.807, P = 0.048) in group HP. DFS analyses were done on 141 patients. Although ER and PR status did not show significant difference in group HP (P = 0.789 and 0.088, respectively), HP-based therapy contributed to better DFS in the ER - and PR - cohorts (P = 0.035 and 0.015, respectively).RESULTSIn total, the pCR occurred in 25 of 87 patients (28.74%) in group H compared with 32 of 55 (58.18%) in group HP. The results revealed that hormone receptor (HR) status was significantly different on pCR in group HP. The odds of pCR for patients who have HR-positive tumors were 0.160 times (P = 0.011) that for patients with HR-negative tumors by multivariable analysis. Moreover, a similar probability of PR-positive (PR +) patients, whatever estrogen receptor (ER) status was, achieving pCR in group HP was observed. The ROC curves showed different anti-HER2 regimens provide worst predictive value in the PR + cohort (N = AUC = 0.521, 95% CI: 0.348-0.694, P = 0.813) compared with the overall cohort (AUC = 0.644, 95% CI: 0.550-0.738, P = 0.004) and ER + cohort (AUC: 0.559, 95% CI: 0.405-0.713, P = 0.451). And PR status (AUC = 0.760, 95% CI: 0.626-0.894, P = 0.001) had a greater predictive value than ER status (AUC = 0.658, 95% CI: 0.508-0.807, P = 0.048) in group HP. DFS analyses were done on 141 patients. Although ER and PR status did not show significant difference in group HP (P = 0.789 and 0.088, respectively), HP-based therapy contributed to better DFS in the ER - and PR - cohorts (P = 0.035 and 0.015, respectively).Compared with ER status, PR status might be a more valuable factor predicting the efficacy of adding pertuzumab into neoadjuvant therapy for HER2 + /N + BC. PR + patients benefit little from the addition of pertuzumab.CONCLUSIONSCompared with ER status, PR status might be a more valuable factor predicting the efficacy of adding pertuzumab into neoadjuvant therapy for HER2 + /N + BC. PR + patients benefit little from the addition of pertuzumab. Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph node-positive (N +) breast cancer (BC) patients according to NCCN guidelines, it is undeniable that many patients achieved pathological complete response (pCR) after trastuzumab (H)-based regimens without adding pertuzumab to treatment. Patients who specifically benefit from pertuzumab must be identified. The aim of this retrospective study was to evaluate progesterone receptor (PR) status as a predictor of response to the addition of pertuzumab in HER2 + /N + breast cancer. One hundred forty-two patients who were diagnosed as HER2 + /N + BC without distant metastasis and followed by neoadjuvant HP-based or H-based therapy were retrospectively included. The endpoints were pCR and disease-free survival (DFS) times. In total, the pCR occurred in 25 of 87 patients (28.74%) in group H compared with 32 of 55 (58.18%) in group HP. The results revealed that hormone receptor (HR) status was significantly different on pCR in group HP. The odds of pCR for patients who have HR-positive tumors were 0.160 times (P = 0.011) that for patients with HR-negative tumors by multivariable analysis. Moreover, a similar probability of PR-positive (PR +) patients, whatever estrogen receptor (ER) status was, achieving pCR in group HP was observed. The ROC curves showed different anti-HER2 regimens provide worst predictive value in the PR + cohort (N = AUC = 0.521, 95% CI: 0.348-0.694, P = 0.813) compared with the overall cohort (AUC = 0.644, 95% CI: 0.550-0.738, P = 0.004) and ER + cohort (AUC: 0.559, 95% CI: 0.405-0.713, P = 0.451). And PR status (AUC = 0.760, 95% CI: 0.626-0.894, P = 0.001) had a greater predictive value than ER status (AUC = 0.658, 95% CI: 0.508-0.807, P = 0.048) in group HP. DFS analyses were done on 141 patients. Although ER and PR status did not show significant difference in group HP (P = 0.789 and 0.088, respectively), HP-based therapy contributed to better DFS in the ER - and PR - cohorts (P = 0.035 and 0.015, respectively). Compared with ER status, PR status might be a more valuable factor predicting the efficacy of adding pertuzumab into neoadjuvant therapy for HER2 + /N + BC. PR + patients benefit little from the addition of pertuzumab. Background Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph node-positive (N +) breast cancer (BC) patients according to NCCN guidelines, it is undeniable that many patients achieved pathological complete response (pCR) after trastuzumab (H)-based regimens without adding pertuzumab to treatment. Patients who specifically benefit from pertuzumab must be identified. The aim of this retrospective study was to evaluate progesterone receptor (PR) status as a predictor of response to the addition of pertuzumab in HER2 + /N + breast cancer. Methods One hundred forty-two patients who were diagnosed as HER2 + /N + BC without distant metastasis and followed by neoadjuvant HP-based or H-based therapy were retrospectively included. The endpoints were pCR and disease-free survival (DFS) times. Results In total, the pCR occurred in 25 of 87 patients (28.74%) in group H compared with 32 of 55 (58.18%) in group HP. The results revealed that hormone receptor (HR) status was significantly different on pCR in group HP. The odds of pCR for patients who have HR-positive tumors were 0.160 times (P = 0.011) that for patients with HR-negative tumors by multivariable analysis. Moreover, a similar probability of PR-positive (PR +) patients, whatever estrogen receptor (ER) status was, achieving pCR in group HP was observed. The ROC curves showed different anti-HER2 regimens provide worst predictive value in the PR + cohort (N = AUC = 0.521, 95% CI: 0.348-0.694, P = 0.813) compared with the overall cohort (AUC = 0.644, 95% CI: 0.550-0.738, P = 0.004) and ER + cohort (AUC: 0.559, 95% CI: 0.405-0.713, P = 0.451). And PR status (AUC = 0.760, 95% CI: 0.626-0.894, P = 0.001) had a greater predictive value than ER status (AUC = 0.658, 95% CI: 0.508-0.807, P = 0.048) in group HP. DFS analyses were done on 141 patients. Although ER and PR status did not show significant difference in group HP (P = 0.789 and 0.088, respectively), HP-based therapy contributed to better DFS in the ER - and PR - cohorts (P = 0.035 and 0.015, respectively). Conclusions Compared with ER status, PR status might be a more valuable factor predicting the efficacy of adding pertuzumab into neoadjuvant therapy for HER2 + /N + BC. PR + patients benefit little from the addition of pertuzumab. Keywords: HER2-positive breast cancer, Progesterone receptor, Neoadjuvant therapy, Pathological complete response BackgroundAlthough neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph node-positive (N +) breast cancer (BC) patients according to NCCN guidelines, it is undeniable that many patients achieved pathological complete response (pCR) after trastuzumab (H)-based regimens without adding pertuzumab to treatment. Patients who specifically benefit from pertuzumab must be identified. The aim of this retrospective study was to evaluate progesterone receptor (PR) status as a predictor of response to the addition of pertuzumab in HER2 + /N + breast cancer.MethodsOne hundred forty-two patients who were diagnosed as HER2 + /N + BC without distant metastasis and followed by neoadjuvant HP-based or H-based therapy were retrospectively included. The endpoints were pCR and disease-free survival (DFS) times.ResultsIn total, the pCR occurred in 25 of 87 patients (28.74%) in group H compared with 32 of 55 (58.18%) in group HP. The results revealed that hormone receptor (HR) status was significantly different on pCR in group HP. The odds of pCR for patients who have HR-positive tumors were 0.160 times (P = 0.011) that for patients with HR-negative tumors by multivariable analysis. Moreover, a similar probability of PR-positive (PR +) patients, whatever estrogen receptor (ER) status was, achieving pCR in group HP was observed. The ROC curves showed different anti-HER2 regimens provide worst predictive value in the PR + cohort (N = AUC = 0.521, 95% CI: 0.348–0.694, P = 0.813) compared with the overall cohort (AUC = 0.644, 95% CI: 0.550–0.738, P = 0.004) and ER + cohort (AUC: 0.559, 95% CI: 0.405–0.713, P = 0.451). And PR status (AUC = 0.760, 95% CI: 0.626–0.894, P = 0.001) had a greater predictive value than ER status (AUC = 0.658, 95% CI: 0.508–0.807, P = 0.048) in group HP. DFS analyses were done on 141 patients. Although ER and PR status did not show significant difference in group HP (P = 0.789 and 0.088, respectively), HP-based therapy contributed to better DFS in the ER − and PR − cohorts (P = 0.035 and 0.015, respectively).ConclusionsCompared with ER status, PR status might be a more valuable factor predicting the efficacy of adding pertuzumab into neoadjuvant therapy for HER2 + /N + BC. PR + patients benefit little from the addition of pertuzumab. Abstract Background Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph node-positive (N +) breast cancer (BC) patients according to NCCN guidelines, it is undeniable that many patients achieved pathological complete response (pCR) after trastuzumab (H)-based regimens without adding pertuzumab to treatment. Patients who specifically benefit from pertuzumab must be identified. The aim of this retrospective study was to evaluate progesterone receptor (PR) status as a predictor of response to the addition of pertuzumab in HER2 + /N + breast cancer. Methods One hundred forty-two patients who were diagnosed as HER2 + /N + BC without distant metastasis and followed by neoadjuvant HP-based or H-based therapy were retrospectively included. The endpoints were pCR and disease-free survival (DFS) times. Results In total, the pCR occurred in 25 of 87 patients (28.74%) in group H compared with 32 of 55 (58.18%) in group HP. The results revealed that hormone receptor (HR) status was significantly different on pCR in group HP. The odds of pCR for patients who have HR-positive tumors were 0.160 times (P = 0.011) that for patients with HR-negative tumors by multivariable analysis. Moreover, a similar probability of PR-positive (PR +) patients, whatever estrogen receptor (ER) status was, achieving pCR in group HP was observed. The ROC curves showed different anti-HER2 regimens provide worst predictive value in the PR + cohort (N = AUC = 0.521, 95% CI: 0.348–0.694, P = 0.813) compared with the overall cohort (AUC = 0.644, 95% CI: 0.550–0.738, P = 0.004) and ER + cohort (AUC: 0.559, 95% CI: 0.405–0.713, P = 0.451). And PR status (AUC = 0.760, 95% CI: 0.626–0.894, P = 0.001) had a greater predictive value than ER status (AUC = 0.658, 95% CI: 0.508–0.807, P = 0.048) in group HP. DFS analyses were done on 141 patients. Although ER and PR status did not show significant difference in group HP (P = 0.789 and 0.088, respectively), HP-based therapy contributed to better DFS in the ER − and PR − cohorts (P = 0.035 and 0.015, respectively). Conclusions Compared with ER status, PR status might be a more valuable factor predicting the efficacy of adding pertuzumab into neoadjuvant therapy for HER2 + /N + BC. PR + patients benefit little from the addition of pertuzumab. |
| ArticleNumber | 296 |
| Audience | Academic |
| Author | Liu, Xiaoyu Song, Xiang Li, Chao Wang, Xinzhao Li, Sumei Liu, Zhaoyun Yu, Zhiyong |
| Author_xml | – sequence: 1 givenname: Xiaoyu surname: Liu fullname: Liu, Xiaoyu – sequence: 2 givenname: Zhaoyun surname: Liu fullname: Liu, Zhaoyun – sequence: 3 givenname: Chao surname: Li fullname: Li, Chao – sequence: 4 givenname: Xiang surname: Song fullname: Song, Xiang – sequence: 5 givenname: Xinzhao surname: Wang fullname: Wang, Xinzhao – sequence: 6 givenname: Sumei surname: Li fullname: Li, Sumei – sequence: 7 givenname: Zhiyong surname: Yu fullname: Yu, Zhiyong |
| BookMark | eNp9kl1rFDEUhgepYFv9A14FBPFmauYjk4w3Ukq1hYJS9DqcySS7WWaSMclsWf-kf8mzuy3tFpG5mHDyvG_O10l25LzTWfa2oGdFIZqPsShbxnNaVjmtCi7y-kV2XNSc51wU7dGT86vsJMYVRbJi1XH25_stiQnSHImNBMjogya9VjbatSYGVPKBWEe0MVaB2hBvCPS9dQsy6ZDm3_MIHQLJE6c99Kt5DS6RtNQBpg0xqL66vC3zyUebtpbgejJsxmlJnO_1Y7wLGmIiCpzSAfXgyOVDap8wMbwe8jsfhh6PKfg4abUTxjT3m22KF0vr4HX20sAQ9Zv7_2n288vlj4ur_Obb1-uL85tcMV6mnOsW2pYr2hlWqrY1vWhZx6hhHShGa6OUFrUWjFVdWRsBSlTYMi2asq_LVlWn2fXet_ewklOwI4SN9GDlLuDDQkJIVg1aipoqaAqqGmPqrgEBVSkYhaZTvO3AoNfnvdc0d6PulXYpwHBgenjj7FIu_FoWlNGmrFp0-HDvEPyvWcckRxuVHgbAocxRlqJpKi5owxB99wxd-Tk47BVSnDPKeF0_UgvACqwzHh9WW1N5zhuGJZUFRersHxR-vR6twg01FuMHgvdPBEscaVpGP8zJehcPQbEHFU46Bm2ksrgKiOELdsDK5Xbv5X7vJY5G7vZeblMvn0kfGvkf0V_WnApl |
| CitedBy_id | crossref_primary_10_3390_cancers15215288 crossref_primary_10_1186_s12957_024_03366_w crossref_primary_10_1038_s41598_024_78176_x crossref_primary_10_1007_s10549_024_07584_4 |
| Cites_doi | 10.1007/s10549-014-2925-7 10.1093/jnci/dji021 10.21873/anticanres.12856 10.1530/JME-20-0091 10.21037/tcr-22-2547 10.1159/000531492 10.1016/S1470-2045(20)30702-6 10.7150/thno.35730 10.1245/s10434-012-2772-x 10.1158/1078-0432.CCR-19-2612 10.1016/S1535-6108(02)00097-1 10.1038/s41467-022-34838-w 10.1200/JCO.19.00108 10.1007/s10549-020-05524-6 10.1126/science.2470152 10.1093/annonc/mdt182 10.1200/JCO.2013.54.5384 10.1002/cncr.31757 10.1007/s12672-016-0275-0 10.5301/JBM.2012.9198 10.1038/35052073 10.3892/ijo.2017.3976 10.2174/1574887112666170529094911 10.1001/jamaoncol.2015.6113 10.1128/MCB.23.3.1095-1111.2003 10.1097/MD.0000000000027632 10.1016/j.breast.2023.07.008 10.1093/annonc/mdw610 10.1007/s12282-012-0415-5 10.1007/978-3-030-73119-9_21 10.1016/j.clbc.2019.05.009 10.1001/jama.2018.19323 10.1001/jamaoncol.2015.1293 10.1038/sj.onc.1203973 10.1200/JCO.2007.12.2747 10.6004/jnccn.2021.0023 10.1016/S1470-2045(11)70336-9 10.1007/s10549-019-05295-9 10.1186/s13058-017-0806-9 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023. BioMed Central Ltd., part of Springer Nature. BioMed Central Ltd., part of Springer Nature 2023 |
| Copyright_xml | – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023. BioMed Central Ltd., part of Springer Nature. – notice: BioMed Central Ltd., part of Springer Nature 2023 |
| DBID | AAYXX CITATION 3V. 7QL 7QO 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO FR3 FYUFA GHDGH K9. M0S M1P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12957-023-03178-4 |
| DatabaseName | CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts ProQuest - Health and Medical ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1477-7819 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_840ca610c6ff4b6a8a32850a6bc79baf PMC10506239 A765840210 10_1186_s12957_023_03178_4 |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GroupedDBID | --- 0R~ 29R 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP W2D WOQ WOW XSB ~8M PMFND 3V. 7QL 7QO 7XB 8FD 8FK AZQEC C1K DWQXO FR3 K9. P64 PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c572t-7e9a997c0bf52c99fd895b50f5bac504fcce84e8553b24f8ac83023e862d429c3 |
| IEDL.DBID | M48 |
| ISSN | 1477-7819 |
| IngestDate | Wed Aug 27 01:25:13 EDT 2025 Thu Aug 21 18:36:40 EDT 2025 Fri Jul 11 02:12:14 EDT 2025 Fri Jul 25 22:50:39 EDT 2025 Tue Jun 17 22:23:19 EDT 2025 Tue Jun 10 21:24:44 EDT 2025 Thu May 22 21:20:40 EDT 2025 Tue Jul 01 02:21:37 EDT 2025 Thu Apr 24 23:02:17 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c572t-7e9a997c0bf52c99fd895b50f5bac504fcce84e8553b24f8ac83023e862d429c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12957-023-03178-4 |
| PQID | 2877505744 |
| PQPubID | 42870 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_840ca610c6ff4b6a8a32850a6bc79baf pubmedcentral_primary_oai_pubmedcentral_nih_gov_10506239 proquest_miscellaneous_2866378065 proquest_journals_2877505744 gale_infotracmisc_A765840210 gale_infotracacademiconefile_A765840210 gale_healthsolutions_A765840210 crossref_citationtrail_10_1186_s12957_023_03178_4 crossref_primary_10_1186_s12957_023_03178_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-09-18 |
| PublicationDateYYYYMMDD | 2023-09-18 |
| PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-18 day: 18 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | World journal of surgical oncology |
| PublicationYear | 2023 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | S Zhao (3178_CR15) 2019; 9 V Boonyaratanakornkit (3178_CR14) 2021; 1329 Y Yarden (3178_CR17) 2001; 2 3178_CR34 M Brandao (3178_CR10) 2020; 26 K Takada (3178_CR20) 2018; 38 DB Agus (3178_CR16) 2002; 2 WJ Gradishar (3178_CR8) 2021; 19 D Harari (3178_CR18) 2000; 19 MSJ McDermott (3178_CR12) 2017; 50 AF Okines (3178_CR35) 2017; 12 S Fujiwara (3178_CR21) 2014; 21 C Lindet (3178_CR23) 2012; 27 NW Harper (3178_CR1) 2019; 19 W Chen (3178_CR29) 2023; 71 F Ma (3178_CR32) 2019; 37 J Baselga (3178_CR19) 2014; 32 D Mauri (3178_CR4) 2005; 97 C Brisken (3178_CR25) 2020; 65 N Niu (3178_CR37) 2022; 13 HL Chen (3178_CR27) 2021; 100 A Romanoff (3178_CR31) 2018; 124 G Bianchini (3178_CR26) 2017; 19 H Lu (3178_CR30) 2023; 12 A Schneeweiss (3178_CR11) 2013; 24 AR Green (3178_CR22) 2014; 145 N Masuda (3178_CR36) 2020; 180 DA Berry (3178_CR5) 2015; 1 KR Broglio (3178_CR6) 2016; 2 L Gianni (3178_CR9) 2012; 13 EA Rakha (3178_CR38) 2007; 25 AG Waks (3178_CR2) 2019; 321 S Park (3178_CR39) 2013; 20 DJ Slamon (3178_CR3) 1989; 244 S Loibl (3178_CR7) 2017; 28 M Krystel-Whittemore (3178_CR28) 2019; 177 L Labriola (3178_CR24) 2003; 23 B Xu (3178_CR33) 2021; 22 SB Matthews (3178_CR13) 2017; 8 |
| References_xml | – volume: 145 start-page: 33 year: 2014 ident: 3178_CR22 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-014-2925-7 – volume: 97 start-page: 188 year: 2005 ident: 3178_CR4 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji021 – volume: 38 start-page: 2285 year: 2018 ident: 3178_CR20 publication-title: Anticancer Res doi: 10.21873/anticanres.12856 – volume: 65 start-page: T81 year: 2020 ident: 3178_CR25 publication-title: J Mol Endocrinol doi: 10.1530/JME-20-0091 – volume: 12 start-page: 1490 year: 2023 ident: 3178_CR30 publication-title: Transl Cancer Res doi: 10.21037/tcr-22-2547 – ident: 3178_CR34 doi: 10.1159/000531492 – volume: 22 start-page: 351 year: 2021 ident: 3178_CR33 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30702-6 – volume: 9 start-page: 4935 year: 2019 ident: 3178_CR15 publication-title: Theranostics doi: 10.7150/thno.35730 – volume: 20 start-page: 1505 year: 2013 ident: 3178_CR39 publication-title: Ann Surg Oncol doi: 10.1245/s10434-012-2772-x – volume: 26 start-page: 2783 year: 2020 ident: 3178_CR10 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-2612 – volume: 2 start-page: 127 year: 2002 ident: 3178_CR16 publication-title: Cancer Cell doi: 10.1016/S1535-6108(02)00097-1 – volume: 13 start-page: 7043 year: 2022 ident: 3178_CR37 publication-title: Nat Commun doi: 10.1038/s41467-022-34838-w – volume: 37 start-page: 2610 year: 2019 ident: 3178_CR32 publication-title: J Clin Oncol doi: 10.1200/JCO.19.00108 – volume: 180 start-page: 135 year: 2020 ident: 3178_CR36 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-020-05524-6 – volume: 244 start-page: 707 year: 1989 ident: 3178_CR3 publication-title: Science doi: 10.1126/science.2470152 – volume: 24 start-page: 2278 year: 2013 ident: 3178_CR11 publication-title: Ann Oncol doi: 10.1093/annonc/mdt182 – volume: 32 start-page: 3753 year: 2014 ident: 3178_CR19 publication-title: J Clin Oncol doi: 10.1200/JCO.2013.54.5384 – volume: 124 start-page: 4314 year: 2018 ident: 3178_CR31 publication-title: Cancer doi: 10.1002/cncr.31757 – volume: 8 start-page: 4 year: 2017 ident: 3178_CR13 publication-title: Horm Cancer doi: 10.1007/s12672-016-0275-0 – volume: 27 start-page: e111 year: 2012 ident: 3178_CR23 publication-title: Int J Biol Markers doi: 10.5301/JBM.2012.9198 – volume: 2 start-page: 127 year: 2001 ident: 3178_CR17 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/35052073 – volume: 50 start-page: 2221 year: 2017 ident: 3178_CR12 publication-title: Int J Oncol doi: 10.3892/ijo.2017.3976 – volume: 12 start-page: 216 year: 2017 ident: 3178_CR35 publication-title: Rev Recent Clin Trials doi: 10.2174/1574887112666170529094911 – volume: 2 start-page: 751 year: 2016 ident: 3178_CR6 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2015.6113 – volume: 23 start-page: 1095 year: 2003 ident: 3178_CR24 publication-title: Mol Cell Biol doi: 10.1128/MCB.23.3.1095-1111.2003 – volume: 100 year: 2021 ident: 3178_CR27 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000027632 – volume: 71 start-page: 69 year: 2023 ident: 3178_CR29 publication-title: Breast doi: 10.1016/j.breast.2023.07.008 – volume: 28 start-page: 497 year: 2017 ident: 3178_CR7 publication-title: Ann Oncol doi: 10.1093/annonc/mdw610 – volume: 21 start-page: 472 year: 2014 ident: 3178_CR21 publication-title: Breast Cancer doi: 10.1007/s12282-012-0415-5 – volume: 1329 start-page: 443 year: 2021 ident: 3178_CR14 publication-title: Adv Exp Med Biol doi: 10.1007/978-3-030-73119-9_21 – volume: 19 start-page: e495 year: 2019 ident: 3178_CR1 publication-title: Clin Breast Cancer doi: 10.1016/j.clbc.2019.05.009 – volume: 321 start-page: 288 year: 2019 ident: 3178_CR2 publication-title: JAMA doi: 10.1001/jama.2018.19323 – volume: 1 start-page: 875 year: 2015 ident: 3178_CR5 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2015.1293 – volume: 19 start-page: 6102 year: 2000 ident: 3178_CR18 publication-title: Oncogene doi: 10.1038/sj.onc.1203973 – volume: 25 start-page: 4772 year: 2007 ident: 3178_CR38 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.12.2747 – volume: 19 start-page: 484 year: 2021 ident: 3178_CR8 publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2021.0023 – volume: 13 start-page: 25 year: 2012 ident: 3178_CR9 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70336-9 – volume: 177 start-page: 61 year: 2019 ident: 3178_CR28 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-019-05295-9 – volume: 19 start-page: 16 year: 2017 ident: 3178_CR26 publication-title: Breast Cancer Res doi: 10.1186/s13058-017-0806-9 |
| SSID | ssj0023353 |
| Score | 2.355102 |
| Snippet | Background Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph... Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph node-positive (N +)... BackgroundAlthough neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph... Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph node-positive (N +)... Abstract Background Although neoadjuvant trastuzumab and pertuzumab (HP)-based regimens are recommended for human epidermal receptor-positive (HER2 +)/lymph... |
| SourceID | doaj pubmedcentral proquest gale crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 1 |
| SubjectTerms | Breast cancer Cancer therapies Care and treatment Chemotherapy Dosage and administration Effectiveness ErbB-2 protein Estrogen receptors Estrogens Evaluation HER2-positive breast cancer Immunotherapy Lymph nodes Lymphatic system Medical prognosis Metastases Metastasis Methods Monoclonal antibodies Neoadjuvant therapy Pathological complete response Patients Pertuzumab Progesterone Progesterone receptor Receptors Statistical analysis Surgery Targeted cancer therapy Therapy Trastuzumab Tumors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG5kD-JFfOLorpYgeJCwmaQ7SXtbZZZBUGRxYW9NP3VkTJaZRJj9k_4lqzrJuFHQi7ehuxK6u76ux6QejL3QJjUFgidB7aETHjKeyMzyhGdmHqTzLrcx2uJDsTzn7y7ExbVWXxQT1pcH7g_uGB0Qq1HH2yIEbgpd6TyrRKoLY0tpdCDpizpvdKYGVyvPRT6myFTF8Ra1migTHE8QxOg38YkaitX6_5TJv8dJXlM8p3fY7cFihJN-pXfZDV_fYzffD9_E77MfH8-A0oK6Lay2oIEiZ8HF1jnfPfT9dGBVg6diEdruoAlAUUT1Z7j0m7a76r5pgwRtA7VvtPvaoXHdQp-YtQM0amG5OMuSPrwLX6lrB-sdogDqxvlf44bi21uwhKMN0F_ysBiX9hoXhtPrJFZoxZ_tphmTPCGWuKUlxmbeD9j56eLT22UytGlIrCizNim91FKWNjVBZFbK4CopjEiDMNqKlAdrfcV9JURuMh4qbanmWO7Rl3KoDW3-kB3UTe0fMUCWOjEvHXLPoysWTEAgldrl0rgshGzG5iPXlB1qmFMrjbWKvkxVqJ7TCt-vIqcVn7FX-2cu-woef6V-Q2DYU1L17TiAmFQDJtW_MDljzwhKqk9l3csQdVKSvUde9oy9jBQkRXADyP0-GQKPgepxTSgPJ5R4--10eoSrGqTPVqEXXJLjyXE7z_fT9CRF1CGWOqJBW7Okz-ozVk1gPtn7dKZefYkVyNEoT9Fulo__x2k9YbeyeDMlCoxDdtBuOn-Ell5rnsZL_RM3AVT1 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest - Health and Medical dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgifmL11AiCDxJut03axhc5ZY9FUOTwYN9CPs-VtV13W2H9J_2XnEnbXatwb0sy7SadXyYzyXwQ8lKbickBPAx2D814SDmTqeWMp2YapPMus9Hb4lM-v-AfFmLRH7hte7fKQSZGQe1qi2fkJ6DZF6hMc_52_YNh1Si8Xe1LaFwnNzB1GaK6WBwMriwT2RAoU-YnW9jbRMGgnQGUwXrio80o5uz_XzL_6y351_Zzdofc7vVGetox-i655qt75ObH_mb8Pvn9-ZxicFC7pcst1RT9Z6mLBXR-etpV1aHLinpMGaHtjtaBoi9RdUnXftO0v9rv2gBBU9PK19p9a0HFbmgXnrWjoNrS-ew8ZZ2TF7xSV46udoAFWtXOH9oNerk31CKaNhQP5ulsGNobGBh0r1jM0wo_m009hHrSmOgWhxhLej8gF2ezL-_nrC_WwKwo0oYVXmopCzsxQaRWyuBKKYyYBGG0FRMerPUl96UQmUl5KLXFzGOZB4vKwZ5os4fkqKor_4hQW0gnpoUD7nkwyIIJAKdCu0wal4aQJmQ6cE3ZPpM5FtRYqWjRlLnqOK3g_SpyWvGEvN4_s-7yeFxJ_Q7BsKfEHNyxod5cqn5JKzCNrQbt0-YhcJPrUmdpKSY6NzABo0NCniOUVBfQupck6rRArQ9t7YS8ihQoS2ACwP0uJAI-A2blGlEejyhBBthx9wBX1cugrTqsmIS82Hfjk-hXB1hqkQY0zgIv1xNSjmA-mvu4p1p-jXnIQTWfgPYsH1_970_IrTSuOQkC4ZgcNZvWPwVNrjHP4nL9A18sS8E priority: 102 providerName: ProQuest |
| Title | PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China |
| URI | https://www.proquest.com/docview/2877505744 https://www.proquest.com/docview/2866378065 https://pubmed.ncbi.nlm.nih.gov/PMC10506239 https://doaj.org/article/840ca610c6ff4b6a8a32850a6bc79baf |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA_3AeKL-Imr5xpB8EGqu23SNILIreyxCHcciwuLLyVJk3Nlbc9uK67_pP-SM2m7Wj3El1KaaUia32Rmmvkg5KnSIx0DeAKQHipgLmSBDA0LWKjHTmY2i4z3tjiLZwv2bsmXe6Qrd9R-wM2Vph3Wk1qU6xffvmzfAMO_9gyfxC83ILO4CED6BABRsIrYPjkEySSwosEp250qhFHks1KOmRCBAFHYBdFc2UdPUPl8_n_v2n96Uv4mmk5ukhutTkmPGxDcIns2v02unban5nfIj_M5xcChekNXG6oo-tbSzBfX-WppU3GHrnJqMZ2EMltaOIp-RvkFvbRlVX-vPysNBFVBc1uo7FMN6ndFm9CtLQW1l86m8zBoHMCgS5VndL0FnNC8yOyv5xo94CtqEGklxZ_2dNoN7RUMDJrXgc_hCrdVWXRhoNQnwcUh-nLfd8niZPr-7SxoCzkEhouwCoSVSkphRtrx0EjpskRyzUeOa2X4iDljbMJswnmkQ-YSZTArWWTB2spAXproHjnIi9zeJ9QImfGxyGAlLRhrTjuAmlBZJHUWOhcOyLhbtdS0Wc6x2MY69dZOEqfNSqfQf-pXOmUD8nz3zmWT4-Of1BMEw44S83P7B0V5kbbsnoLZbBRopiZ2julYJSoKEz5SsYYJaOUG5DFCKW2CXXe7THosUCNEO3xAnnkKRD5MAFa_CZeAz4AZu3qURz1K2B9Mv7mDa9qxVwp2skDTlMF0nuya8U30uQMs1UgD2qjAg_cBSXow782935KvPvoc5aC2j0Czlg_-o_uH5HroGU_CjnFEDqqyto9A1av0kOyLpRiSw8n07Hw-9D9Mhp6n4TqffPgJNixXYg |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ZbxMxELZKkYAXxCkWCjUSiAe06sZr74GEUIFWKT2EqlbKm_FZispuSTag8KP4K_wlZrzZhAWpb32L7NmNnRnPfBPPQcgzpROdgfDEYD1UzD3jcckMjznTA19aZ1MToi0OsuEx_zASoxXyq8uFwbDKTicGRW1rg_-RbwCyzxFMc_7m_FuMXaPwdrVrodGKxa6b_QCXbfJ65z3w9zlj21tH74bxvKtAbETOmjh3pSrL3CTaC2bK0tuiFFokXmhlRMK9Ma7grhAi1Yz7QhkskZU6gP4WlLdJ4b1XyFUwvAk6e_lo6eClqUi7xJwi25iALRV5DOMxHB3w1njP-IUeAf9bgn-jM_8yd9u3yM05TqWbrWDdJiuuukOu7c9v4u-S3x8PKSYjTSf0dEIVxXhdakPDnu-Otl186GlFHZaoUGZGa08xdqk6oedu3Ex_Tr8qDQRNTStXK_tlCpC-oW062IwClKbDrUMWt0Fl8EpVWXo2A9mjVW3dclxjVH1DDUrvmOJFAN3qlvYKFgbTZ3GoCwsfm3HdpZbSUFgXlxhaiN8jx5fCxvtktaor94BQk5dWDHIL3HPgAHrtQXxzZdNSW-Y9i8ig45o088rp2MDjTAYPqshky2kJ75eB05JH5OXimfO2bsiF1G9RGBaUWPM7DNTjEzlXIRJccaMA7ZrMe64zVaiUFSJRmYYNaOUjso6iJNsE2oXmkps5okz07SPyIlCg7oINAPfbFAz4GbAKWI9yrUcJOsf0pztxlXOdN5HLExqRp4tpfBLj-ECWpkgDCDfHy_yIFD0x7-29P1Odfg51z8EVSACtlw8v_vZ1cn14tL8n93YOdh-RGyycvxKU0RpZbcZT9xhQZKOfhKNLyafL1hV_AN5RiQA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PR+status+is+a+more+decisive+factor+in+efficacy+of+adding+pertuzumab+into+neoadjuvant+therapy+for+HER2-positive+and+lymph+node-positive+breast+cancer+than+ER+status%3A+a+real-world+retrospective+study+in+China&rft.jtitle=World+journal+of+surgical+oncology&rft.au=Liu%2C+Xiaoyu&rft.au=Liu%2C+Zhaoyun&rft.au=Li%2C+Chao&rft.au=Song%2C+Xiang&rft.date=2023-09-18&rft.issn=1477-7819&rft.eissn=1477-7819&rft.volume=21&rft.issue=1&rft.spage=296&rft_id=info:doi/10.1186%2Fs12957-023-03178-4&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-7819&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-7819&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-7819&client=summon |